New drug combo could slash kidney transplant wait times for Hard-to-Match patients
NCT ID NCT04827979
First seen Jan 23, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether two drugs, daratumumab and belatacept, can lower immune sensitivity in kidney transplant candidates who are highly sensitized, meaning their bodies reject most donor kidneys. Nineteen participants with very high antibody levels receive the drugs to see if they become compatible with more donors. The goal is to help them get a transplant sooner and reduce the risk of rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California at San Francisco Medical Center
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.